GLAXOSMITHKLINE PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,292 INR | +13.23% |
|
+16.15% | +20.77% |
| 05-17 | GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales | RE |
| 05-09 | Drugmaker Abbott India posts Q4 profit rise on higher sales | RE |
| Sales 2024 | 34.54B 415M 32.66B | Sales 2025 * | 36.49B 438M 34.51B | Capitalization | 388B 4.66B 367B |
|---|---|---|---|---|---|
| Net income 2024 | 5.9B 70.86M 5.58B | Net income 2025 * | 7.68B 92.21M 7.26B | EV / Sales 2024 | 9.53 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 10.6 x |
| P/E ratio 2024 |
55.8
x | P/E ratio 2025 * |
50.6
x | Employees | 3,680 |
| Yield 2024 * |
1.32% | Yield 2025 * |
1.38% | Free-Float | 24.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +13.23% | ||
| 1 week | +16.16% | ||
| Current month | +9.80% | ||
| 1 month | +20.62% | ||
| 3 months | +1.56% | ||
| 6 months | +44.24% | ||
| Current year | +20.77% |
1 week
1 970.00
2 342.90
1 month
1 846.252 342.90
Current year
1 825.052 649.95
1 year
1 265.002 649.95
3 years
1 228.002 649.95
5 years
1 046.402 649.95
10 years
1 020.002 649.95
| Managers | Title | Age | Since |
|---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 54 | 30/11/22 |
Juby Chandy
DFI | Director of Finance/CFO | - | 31/03/22 |
Simrat Sohal
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Renu Sud Karnad
CHM | Chairman | 70 | 31/03/19 |
Manu Anand
BRD | Director/Board Member | 64 | 15/05/22 |
| Director/Board Member | 74 | 29/03/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 112 M€ | +5.41% | - | |
| 0.00% | 32 M€ | +9.08% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 2,292 | +13.23% | 58,699 |
| 16/05/24 | 2,024 | +1.87% | 2,279 |
| 15/05/24 | 1,987 | -0.62% | 4,647 |
| 14/05/24 | 1,999 | +0.08% | 1,910 |
| 13/05/24 | 1,998 | +1.25% | 4,982 |
Delayed Quote Bombay S.E., May 17, 2024 at 11:26 am
More quotes
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Sector
Pharmaceuticals
Calendar
21/07/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2,292
INR
Average target price
2,141
INR
Spread / Average Target
-6.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.77% | 4.11B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 500660 Stock
